Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cervical Cancer
Cervarix, GSK's candidate vaccine for cervical cancer, demonstrated sustained efficacy
May 10th, 2006
Cervarix, GlaxoSmithKline's (GSK) candidate vaccine for cervical cancer prevention, showed 100% efficacy over 4.5 years against precancerous lesions associated with human papillomavirus (HPV) types 16 and 18, the two most common cancer-causing HPV types, a new follow-up study shows. HPV 16 and 18 are responsible for more than 70% of cervical cancers globally. GSK's candidate vaccine for cervical cancer is formulated with the proprietary innovative adjuvant system AS04, selected to ensure this vaccine confers strong and sustained antibody levels in women. The study, published in The Lancet, also found that HPV 16 and 18 antibodies were detected...
Source: Vaccine Weekly (2006-05-10)
|
